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AbstrAct
Introduction Oral corticosteroids are the first-line 
treatment for idiopathic childhood nephrotic syndrome. 
Most children experience several relapses, needing 
repeated courses of corticosteroid therapy. This exposes 
them to side effects and long-term complications. For most 
patients, long-term prognosis is for complete resolution of 
the disease over time and maintenance of normal kidney 
function. Therefore, it is vital to focus on minimising adverse 
events of the disease and its therapy. Unfortunately, no 
randomised controlled trials are available to determine the 
optimal corticosteroid treatment of an infrequent relapse of 
nephrotic syndrome. Recent studies show that treatment 
schedules for the first episode can safely be shortened 
to 2 months. The hypothesis of the REducing STEroids in 
Relapsing Nephrotic syndrome (RESTERN) study is that a 
4-week reduction of alternate-day steroids after inducing 
remission is effective and safe, reduces steroid exposure by 
35% on average and is therefore preferable.
Methods and analysis The RESTERN study is a 
nationwide, double-blind, randomised, placebo-controlled, 
non-inferiority intervention study. Children aged 1–18 years 
with a relapse of steroid-sensitive nephrotic syndrome 
are eligible for this study. Study subjects (n=144) will be 
randomly assigned to either current standard therapy in 
the Netherlands or a reduced prednisolone schedule. The 
primary outcome of the RESTERN study is the time to first 
relapse after the final prednisolone dose. The secondary 
outcomes are the number or relapses, progression 
to frequent relapsing or steroid dependent nephrotic 
syndrome and the cumulative dosage of prednisolone 
during the study period.
Ethics and dissemination This non-inferiority trial will be 
performed in accordance with the Declaration of Helsinki 
and has been approved by the medical ethical committee 
of Arnhem-Nijmegen and the Dutch Competent Authority 
(Central Committee on Research Involving Human 
Subjects, CCMO). After completion of this study, results will 
be published in national and international peer-reviewed 
scientific journals. Papers will be published according to 
CCMO guidelines. The final report will be made available to 
trial participants.
trial registration number NTR5670, EudraCT no 2016-
002430-76.
IntroductIon
Nephrotic syndrome is characterised by 
the triad of severe proteinuria, hypoalbu-
minaemia and oedema. It is one of the most 
common glomerular diseases in children with 
an incidence of 1–7 per 100 000 children per 
year (Dutch data: 1.52/100 000) and a prev-
alence of 16 per 100 000 children.1–3 Most 
children have minimal change nephrotic 
syndrome and will have favourable prognosis 
with complete resolution of the disease over 
time and maintenance of normal kidney 
function.4
For over 60 years, corticosteroids have 
been the first-line treatment for idiopathic 
nephrotic syndrome in children as over 
80%–90% of patients achieve complete 
remission after prednisolone treatment.5 6 
Yet, over 80% of the patients experience one 
or more relapses and around 50% suffer from 
frequent relapses, thereby needing addi-
tional courses of corticosteroid therapy.7 This 
exposes them to the side effects and long-
term complications of corticosteroid therapy, 
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Protocol
strengths and limitations of this study
 ► Double-blind, randomised, placebo-controlled study.
 ► Nationwide inclusion.
 ► Large study cohort.
 ► Two common practices in the Netherlands regarding 
the current treatment of relapsing nephrotic 
syndrome.
 ► Side effects and toxicity of steroids might jeopardise 
the double-blind design of the study.
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box Inclusion and exclusion criteria
Inclusion criteria
 ► Age over 1 and less than 18 years
 ► Steroid-sensitive nephrotic syndrome
 ► At least one episode of nephrotic syndrome in the preceding 
24 months that was treated with prednisolone
 ► The last prednisolone use (at a dose over 10 mg/m2 on alternate 
days) for the treatment of a previous episode was at least 4 weeks 
ago
 ► Subjects without maintenance immunosuppressive therapy
 ► Subjects with maintenance immunosuppressive therapy
 – Long-term immunosuppressive therapies: levamisole, 
ciclosporin, tacrolimus, mycophenolate mofetil (Cellcept), 
mycophenolate sodium (Myfortic), prednisolone maximum 
of 4 mg/m2 on alternate days
 – Cyclophosphamide (oral or intravenous), at least 3 months 
postcompletion of therapy
 – A single dose or course of intravenous rituximab, at least 
3 months postcompletion of therapy
 ► Signed informed consent from the parent or legal representative 
and/or the patient, depending on the age of the patient
Exclusion criteria
 ► Steroid resistant nephrotic syndrome
 ► Receiving or within 3 months after receiving, cyclophosphamide or 
rituximab
 ► Daily prednisolone maintenance therapy at any dose
 ► Alternate-day prednisolone maintenance therapy at a dose over 
4 mg/m2
 ► Documented or suspected significant non-compliance
 ► Pregnancy
 ► Stimulant drug use
 ► Comorbidity
 – Kidney transplant recipient
 – Any disease that requires the variation in oral prednisolone to be 
at the discretion of the treating physician(s)
 ► Concomitant use of moderate and strong CYP3A inducers
 ► Concomitant use of moderate and strong CYP3A inhibitors, other 
than ciclosporin
such as growth retardation (8%–16%), osteopaenia 
(13%–63%), mood disorders and cataract (6%–20%).8–11 
The currently used treatment regimens for a nephrotic 
syndrome relapse are mostly based on practice guidelines 
of the International Study of Kidney Disease in Children 
(ISKDC)12 and the Arbeitsgemeinschaft für Pädiatrische 
Nephrologie (APN).13 In the Netherlands, the standard 
treatment schedule consists of 60 mg/m2 prednisolone 
daily until complete remission is achieved for 3 days, 
followed by 40 mg/m2 prednisolone on alternate days for 
4–6 weeks.14 15
Several trials have been conducted to study the dura-
tion of the initial corticosteroid treatment regimen, as 
Hodson et al suggested that a prolonged period of pred-
nisolone might reduce chances of subsequent relapses.16 
A previous nationwide study in the Netherlands 
addressed the issue of duration of corticosteroids for the 
initial presentation and showed that the duration had no 
impact on subsequent relapses.7 A few recent, well-con-
ducted trials suggest that it may be safe to reduce the 
duration and thereby cumulative dose of corticosteroid 
therapy for the initial episode of nephrotic syndrome 
from 6 to 2 or 3 months.17–21 With recent studies showing 
no benefit for longer duration of initial prednisolone 
treatment, one may conclude that we still don’t know the 
optimal treatment duration of relapses. In addition, as 
stated in the KDIGO (Kidney Disease: Improving Global 
Outcomes) clinical practice guideline glomerulone-
phritis, “there are no RCTs examining relapse regimens 
with corticosteroids in infrequent relapsing nephrotic 
syndrome”.22 With the current evidence against longer 
steroid therapy for the initial treatment, the time is now 
to determine whether this holds true for treatment of 
relapses as well, in both children with and without main-
tenance immunosuppressive therapy.
The aim of the RESTERN study (REducing STEroids in 
Relapsing Nephrotic syndrome) is to assess the safety and 
effectiveness of a reduced alternate day steroid schedule 
for treatment of a nephrotic syndrome relapse in compar-
ison with the current standard therapy.
MEthods And AnAlysIs
trial design and setting
The RESTERN study is designed as a nationwide, double-
blind, randomised, placebo-controlled, non-inferi-
ority intervention study with two treatment arms. The 
study is performed and coordinated by a single centre 
(Radboudumc Amalia Children’s Hospital) where the 
research team is instituted, with inclusion of patients 
throughout the Netherlands from all secondary and 
tertiary hospitals.
Eligibility criteria
Children aged over 1 and less than 18 years with 
steroid-sensitive nephrotic syndrome will be assessed for 
possible inclusion in the study. A detailed description of 
the inclusion and exclusion criteria is shown in box.
study objectives
The primary objective of this study is to investigate 
the effectiveness of a reduced steroid schedule for the 
treatment of a relapse in children with steroid-sensi-
tive nephrotic syndrome. Secondary objectives are the 
following:
 ► To study the influence of maintenance immunosup-
pressive therapy on the effectiveness of a reduced 
steroid schedule for the treatment of a relapse in 
children with steroid-sensitive nephrotic syndrome. 
Maintenance immunosuppressive therapies include 
levamisole, ciclosporin, tacrolimus, mycophenolate 
mofetil and mycophenolate sodium, and alternate-day 
prednisolone with a maximum of 4 mg/m2;
 ► To investigate the occurrence of relapses, frequency 
of relapses and progression to steroid dependent and 
frequent relapsing nephrotic syndrome in children 
with nephrotic syndrome under the standard treat-
ment regimen;
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Figure 1 Intervention schedule and study procedures. AD, alternate days.
 ► To study the influence of maintenance immuno-
suppressive therapy on the occurrence of subse-
quent relapses, frequency of subsequent relapses 
and progression to steroid dependent and frequent 
relapsing nephrotic syndrome under the standard 
regimen;
 ► To study the effectiveness of a reduced steroid 
schedule for the treatment of a relapse and occur-
rence and frequency of subsequent relapses in chil-
dren with steroid dependent nephrotic syndrome.
Interventions
Eligible patients will be randomised between stan-
dard prednisolone treatment and a reduced treatment 
schedule. At the start of a relapse, participants are treated 
according to the current standard therapy, consisting of 
daily oral prednisolone (60 mg/m2). After 3 days of remis-
sion, defined as 3 consecutive days of absent proteinuria 
based on urine dipstick analysis, standard care dictates 
that prednisolone is changed to an alternate-day dosing 
of 40 mg/m2 with a maximum of 40 mg. After 2 weeks of 
alternate-day prednisolone, participants are randomised 
between the two treatment arms. The standard treatment 
group will receive an additional 4 weeks of alternate-day 
oral prednisolone (40 mg/m2, with a maximum of 40 mg) 
and the placebo group will receive 4 weeks of alter-
nate-day oral placebo (figure 1). Prednisolone (5 mg/
mL) or placebo will be provided as an oral solution (see 
Investigational medicinal product section).
Children will be withdrawn if they are unable to take 
the study medication and will be treated according to 
the standard treatment regimen (oral prednisolone 
40 mg/m2 on alternate days). Maintenance immuno-
suppressive therapy, including levamisole, ciclosporin, 
tacrolimus, mycophenolate mofetil and mycophenolate 
sodium, is continued throughout the treatment period. 
Alternate-day prednisolone maintenance therapy with 
a maximum of 4 mg/m2, is discontinued during the 
non-randomised treatment and restarted after rando-
misation, administered at the same day as the study 
medication. Antihypertensive agents, antiproteinuric 
agents and/or diuretics may be continued at the discre-
tion of the treating physician.
All children will be followed for 2 years and subsequent 
nephrotic syndrome relapses will be treated according 
to the current standard treatment protocol in the 
Netherlands.
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Table 1 Study questionnaires
Questionnaire Information Time points
Questionnaire 1 General information, 
medical history, 
relapse information
At the start of 
alternate day 
prednisolone
Questionnaire 2 Information study 
medication period
One week after 
initiation of study 
medication
Questionnaire 3 Information after 
study medication 
period
After the final dose 
of study medication
Questionnaire 4 Information 
subsequent relapses
At the time of a new 
relapse
Questionnaire 5 Follow-up 1 year One year after 
randomisation
Questionnaire 6 Follow-up 2 years Two years after 
randomisation
Investigational medicinal product
A prednisolone or placebo solution (5 mg/mL) will 
be produced compliant with current Good Manufac-
turing Practice at the department of pharmacy of our 
institute. The standardised formulation of the oral 
solution is based on the Dutch Pharmacists Formulary. 
The investigational medicinal product is an aqueous 
solution preserved with methylparaben, buffered at a 
pH of 7.1 with a phosphate buffer and contains sorbitol 
and banana essence to mask the bitter taste of pred-
nisolone sodium phosphate. For the placebo, prednis-
olone sodium phosphate is left out of the product. A 
pilot palatability study of the investigational medicinal 
product showed no relevant visual or taste differences 
of the drug or placebo. Drug dispensing and account-
ability is performed on individual basis from the central 
pharmacy.
outcomes
The primary outcome of the RESTERN study is the time 
to first relapse. This is defined as the time (in days) 
from the final prednisolone dose until the first day of 
treatment of the next relapse.
Secondary outcomes include the following:
1. The number of relapses per patient after the final 
prednisolone dose, censored at 12 and 24 months of 
follow-up;
2. Progression to frequent relapsing nephrotic syn-
drome, defined as four or more relapses in any 
12-month period (KDIGO criteria), censored at 
24 months of follow-up;
3. Progression to steroid dependent nephrotic syn-
drome, defined as two consecutive relapses during 
corticosteroid therapy or within 14 days of ceasing 
therapy (KDIGO criteria), censored at 24 months of 
follow-up;
4. Cumulative dosage of prednisolone (mg/m2) during 
study period, censored at 12 and 24 months of follow-
up.
Participant timeline
During the period of daily prednisolone, participants 
determine the timing of remission by daily urine 
dipstick analysis. In order to objectively establish 
remission of nephrotic syndrome, participants are 
requested to deliver a urine sample to the local hospital 
within 5 days of attaining remission to confirm the 
absence of proteinuria. During the 2 weeks of alter-
nate-day prednisolone and the subsequent 4 weeks of 
study medication, participants are requested to check 
their urine for proteinuria at least weekly. In addi-
tion, patients are requested to fill out digital question-
naires at different time points (figure 1). As shown in 
table 1, follow-up information will be collected at 1 
and 2 years after randomisation and when a relapse 
occurs.
sample size
The sample size calculation is based on the non-inferi-
ority design and calculated for the primary outcome: 
time to first relapse after the final prednisolone dose. 
Based on previous data, average time to relapse in 
the first year is approximately 185 days with an SD of 
120 days.7 Using the power calculation for a non-in-
feriority trial with a continuous primary outcome, a 
power of 80% and a non-inferiority limit of 50 days, 72 
patients per group are required. Using a Cox propor-
tional hazard time-to-relapse analysis (survival analysis), 
similar numbers can be calculated. With an estimated 
prevalence of nephrotic syndrome of 15 in every 
100 000 children, a population most at risk between the 
ages of 2 and 12 years, about 270 children may be at risk 
of developing a nephrotic syndrome relapse each year. 
The necessary inclusion rate is therefore approximately 
50%. Subjects will be replaced after withdrawal. Based 
on withdrawal rates of a previous nephrotic syndrome 
clinical trial in the Netherlands7 a maximum of 23 
subjects (16%) will be replaced. The reason for with-
drawal will be recorded in the medical status report and 
the trial master file.
recruitment
Study subjects will be notified about the existence of 
the RESTERN study via their treating physician, the 
patient associations and/or the study website (www. 
restern. nl). Written informed consent for participation 
will be obtained from the parents or legal representa-
tive(s) and/or the patient, depending on the age of the 
patient.
randomisation and blinding
Participants will be randomly allocated in a 1:1 ratio to 
receive either prednisolone or placebo. The randomisa-
tion will be performed by the pharmacy of our institute 
using the data management system Castor Electronic 
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Data Capture23 with stratification for treatment with 
immunosuppressive maintenance therapy. Castor uses 
a variable block algorithm with random blocks of 4, 6 
or 8. The randomisation list remains preserved by the 
pharmacy and will not be accessible to the investigators 
until the end of the follow-up of the last patient. An 
unblinding procedure at the hospital pharmacy depart-
ment will be available at all times. The true group allo-
cation will be unmasked only if necessary and after the 
database is locked.
data collection
Participants are requested to maintain a digital study log 
in which results from dipstick analysis, medication and 
special remarks are gathered. In addition, participants 
receive digital questionnaires about their medical history, 
previous relapses and the current nephrotic syndrome 
relapse. Moreover, the digital questionnaires include ques-
tions about side effects and steroid toxicity at different 
time points, for example, during the period of daily pred-
nisolone, alternate-day prednisolone and study medica-
tion. First, patients are asked if the different side effects 
were present during the specific time period. Second, the 
level of inconvenience is assessed (ranging from not at all 
inconvenient to very inconvenient). Local paediatricians 
and paediatric nephrologists will be requested to provide 
patient information at different time points. Patients 
randomised who did not take their allocated treatment 
will be considered as having deviated from the protocol. 
If a patient or their representative withdraws consent for 
data collection, only data up to the point of withdrawal 
will be used in the analysis.
data management
The study will use the Good Clinical Practice (GCP) 
compliant, web-based application Castor Electronic Data 
Capture to record data.23 Data will be entered in the case 
report form in Castor by the coordinating investigators 
at the Radboudumc. The digital questionnaires will auto-
matically be uploaded in the data management system.
statistical analysis
Statistical analysis will be conducted using IBM SPSS Statis-
tics. A p value <0.05 will be considered statistically signifi-
cant. The main analysis will consist of an intention-to-treat 
analysis. Participants who are lost to follow-up or in whom 
trial medication is stopped prematurely will be analysed 
according to their allocated groups. In addition, as inten-
tion-to-treat analysis may increase the risk of type 1 errors 
in a non-inferiority trial, a per-protocol analysis will also 
be conducted.24 Missing baseline and outcome data will 
not be imputed. When a patient is lost to follow-up or has 
withdrawn consent, all available data up until withdrawal 
of consent or loss to follow-up will be used. Discrete vari-
ables will be summarised by frequencies and percentages. 
Continuously distributed variables will be summarised 
using either mean and SD for data with normal distri-
bution or median and IQR for non-normally distributed 
data. Further details regarding statistical analysis of the 
primary and secondary outcomes can be found in the 
statistical analysis plan (online supplementary file 1). 
Monitoring
As the standard treatment group will receive the current 
standard therapy for a nephrotic syndrome relapse in the 
Netherlands, no specific safety surveillance is needed for 
this group. The placebo arm provides the participants 
with a reduced prednisolone exposure, which is there-
fore unlikely to result in any adverse events. However, 
the main concern in this study is that the reduced treat-
ment schedule may result in an earlier relapse, which 
is the primary endpoint of the study. An external Data 
Safety and Monitoring Board (DSMB) will be convened 
to monitor safety outcomes and to provide the principal 
investigator with recommendations regarding reconsider-
ation of the trial. The DSMB will consist of two members: 
a methodologist and a paediatric nephrologist with expe-
rience in clinical trials, both independent of the trial. 
Interim analysis performed by the DSMB will take place 
3 months after the first 40 participants have received study 
medication. Aim is to check for a significant difference 
in relapse rate between the two groups. Further details 
about the interim analysis can be found in the statistical 
analysis plan. An independent research coordinator will 
monitor the study to verify that the rights and well-being 
of human subjects are protected, the reported trial data 
are accurate, complete and verifiable from source docu-
ments and the conduct of the trial is in compliance with 
the currently approved protocol and GCP. The coordi-
nating investigators will report the serious adverse events 
and will submit an annual safety report to the medical 
ethical committee and competent authority.
EthIcs And dIssEMInAtIon
Ethics approval
The RESTERN study has been approved by the medical 
ethical committee of Arnhem-Nijmegen and the Dutch 
Competent Authority (Central Committee on Research 
Involving Human Subjects, CCMO). The registration 
number of the RESTERN study is NL8185.091.16. The 
project will be conducted in line with the Declaration 
of Helsinki. In addition, all researchers will follow the 
guidelines for GCP and trial outcomes will be reported 
in line with the Consolidated Standards of Reporting 
Trials guidelines.25 Any substantial amendments or modi-
fications of the protocol will be presented to the medical 
ethical committee and, when approved, be notified to 
the Competent Authority compliant with European 
regulations.
consent
Written informed consent for participation will be 
obtained from the parents or legal representatives and/or 
the patient, depending on the age of the patient. Patients 
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will be informed that withdrawal from the study is possible 
at any time at their own discretion without necessarily 
giving reasons. The ‘code of conduct involving minors’ 
will be used as guideline to respond appropriately to resis-
tance of subjects to study procedures as established by the 
Paediatric Association of the Netherlands.
confidentiality
All patients have their own unique patient identifica-
tion number as allocated by the hospital administration. 
Source data will be stored confidentially in the hospital 
information system under the subject’s identification 
number. Participants will also receive an identification 
code, all final study data will be kept under this identi-
fication number. The investigators safeguard the key to 
the code. Handling of personal data will comply with the 
Dutch Personal Data Protection Act. Data will be stored 
until 15 years after publication.
dissemination policy
The trial is registered on the Dutch Trial Registry, trial 
number NTR5670, prior to the start of inclusion.26 
After completion of this study, results will be published 
in national and international peer-reviewed scientific 
journals. Papers will be published according to CCMO 
guidelines. The final report will be made available to trial 
participants.
dIscussIon
The RESTERN study aims to demonstrate that relapses of 
nephrotic syndrome in children can be treated effectively 
and safely by a reduced duration of alternate day pred-
nisolone. Using a nationwide, double-blind, randomised, 
placebo-controlled, non-inferiority study, the hypothesis 
will be tested.
Currently, corticosteroid treatment duration in children 
with infrequent relapses of steroid-sensitive nephrotic 
syndrome is based on empirical recommendations from 
the ISKDC and APN. The RESTERN study is the first 
randomised placebo-controlled clinical trial to investigate 
a reduced corticosteroid schedule for the treatment of 
relapsing nephrotic syndrome in childhood. So far, most 
studies have been conducted to investigate the initial 
treatment schedule. Recently, it has been shown that a 
reduction in prednisolone duration for the treatment of 
a first presentation of nephrotic syndrome in children, 
with or without increased cumulative dosage, is clinically 
safe and results in similar treatment outcomes, while 
potentially reducing side effects.17 18 20 21 For frequent 
relapsing nephrotic syndrome, an abstract from a single 
randomised controlled trial suggests that children with 
relapsing steroid-sensitive nephrotic syndrome relapse 
less frequently if treated with tapering doses of predniso-
lone for 7 months compared with the standard treatment 
of 2 months. Unfortunately, these results have never been 
published, which makes it impossible to examine them 
closely and evaluate for any bias.18 27
In this study, a treatment duration of 6 weeks alter-
nate-day prednisolone after inducing remission for the 
standard therapy group was chosen as this is the current 
standard therapy in the Netherlands for the treatment of 
a nephrotic syndrome relapse. As the KDIGO recommen-
dation of at least 4 weeks alternate-day steroid treatment is 
based on a rather small study,28 the Dutch guidelines tradi-
tionally follow the 6-week alternate-day steroid schedule 
described by the APN. However, a potential limitation of 
this study could be that some clinicians already reduced 
the alternate-day treatment schedule from 6 to 4 weeks 
after inducing remission based on the notion of this in the 
KDIGO guideline.22 Our choice of 6 weeks alternate-day 
prednisolone may therefore discourage eligible patients 
to participate in our study as this may increase the pred-
nisolone duration for some patients. The use of different 
treatment protocols in the Netherlands underlines the 
need for our randomised controlled trial to determine 
the optimal dosing regimen for a nephrotic syndrome 
relapse. In case non-inferiority is shown, our results are 
also transferable to the KDIGO recommendation of at 
least 4 weeks of alternate-day steroid treatment. However, 
in case inferiority is shown, additional research is needed.
The results of the RESTERN study may provide 
evidence to adapt current recommendations for national 
and possibly international guidelines to treat children 
with relapsing nephrotic syndrome. If corticosteroid 
exposure could be reduced to treat relapses of nephrotic 
syndrome, this would reduce the toxicity of predniso-
lone and thereby decrease the side effects and long-term 
complications associated with corticosteroid therapy in 
children with relapsing nephrotic syndrome.
trial status
The study started recruitment in December 2016 and is 
currently recruiting.
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